Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis

无容量 阿维鲁单抗 阿替唑单抗 易普利姆玛 彭布罗利珠单抗 医学 杜瓦卢马布 肿瘤科 内科学 不利影响 免疫疗法 癌症
作者
Ze Xiang,Jiayuan Li,Zhengyu Zhang,Chao Cen,Wei Chen,Bin Jiang,Yiling Meng,Ying Wang,Björn Berglund,Guangju Zhai,Jian Wu
出处
期刊:Frontiers in Pharmacology [Frontiers Media]
卷期号:13 被引量:12
标识
DOI:10.3389/fphar.2022.883655
摘要

Immunotherapy with immune checkpoint inhibitor (ICI) drugs is gradually becoming a hot topic in cancer treatment. To comprehensively evaluate the safety and efficacy of ICI drugs, we employed the Bayesian model and conducted a network meta-analysis in terms of progression-free survival (PFS), overall survival (OS) and severe adverse events (AEs). Our study found that treatment with ipilimumab was significantly worse than standard therapies in terms of PFS, whereas treatment with cemiplimab significantly improved PFS. The results also indicated that cemiplimab was the best choice for PFS. Treatment with nivolumab, pembrolizumab and nivolumab plus ipilimumab significantly improved OS compared to standard therapies. In terms of OS, cemiplimab was found to be the best choice, whereas avelumab was the worst. In terms of severe AEs, atezolizumab, avelumab, durvalumab, nivolumab, and pembrolizumab all significantly reduced the risk of grade 3 or higher AEs compared to standard therapy. The least likely to be associated with severe AEs were as follows: cemiplimab, avelumab, nivolumab, atezolizumab, and camrelizumab, with nivolumab plus ipilimumab to be the worst. Therefore, different ICI drug therapies may pose different risks in terms of PFS, OS and severe AEs. Our study may provide new insights and strategies for the clinical practice of ICI drugs.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
萱萱发布了新的文献求助10
1秒前
2秒前
12应助DODODO采纳,获得50
3秒前
5秒前
xinxin完成签到,获得积分10
5秒前
阿盛发布了新的文献求助10
6秒前
6秒前
香蕉觅云应助EF采纳,获得10
7秒前
8秒前
8秒前
lydiaabc完成签到,获得积分10
9秒前
10秒前
bji完成签到,获得积分10
10秒前
10秒前
hmv发布了新的文献求助10
10秒前
轶6完成签到,获得积分10
13秒前
13秒前
14秒前
张鱼丸子发布了新的文献求助30
16秒前
17秒前
lindalin发布了新的文献求助10
17秒前
香蕉觅云应助xc采纳,获得10
17秒前
lin完成签到 ,获得积分10
17秒前
负负得正完成签到,获得积分10
17秒前
李健应助qxz采纳,获得10
18秒前
萱萱发布了新的文献求助10
18秒前
网站技术人员完成签到,获得积分10
19秒前
xueshufengbujue完成签到,获得积分10
22秒前
笑笑完成签到,获得积分10
23秒前
Li发布了新的文献求助10
23秒前
hxm发布了新的文献求助10
23秒前
故酒应助不安梦桃采纳,获得10
25秒前
领导范儿应助diudiu采纳,获得10
25秒前
26秒前
26秒前
26秒前
娃娃哈发布了新的文献求助10
26秒前
26秒前
李li完成签到,获得积分10
27秒前
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Zeolites: From Fundamentals to Emerging Applications 1500
Encyclopedia of Materials: Plastics and Polymers 1000
Architectural Corrosion and Critical Infrastructure 1000
Early Devonian echinoderms from Victoria (Rhombifera, Blastoidea and Ophiocistioidea) 1000
Hidden Generalizations Phonological Opacity in Optimality Theory 1000
Handbook of Social and Emotional Learning, Second Edition 900
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4924525
求助须知:如何正确求助?哪些是违规求助? 4194571
关于积分的说明 13029123
捐赠科研通 3966454
什么是DOI,文献DOI怎么找? 2173951
邀请新用户注册赠送积分活动 1191426
关于科研通互助平台的介绍 1100971